Skip to content

Rheumatoid Arthritis and Treatment of Periodontitis: a Randomized Clinical Trial.

Rheumatoid Arthritis and Treatment of Periodontitis: a Randomized Clinical Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05271890
Enrollment
30
Registered
2022-03-09
Start date
2014-08-25
Completion date
2019-02-28
Last updated
2022-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Rheumatoid, Periodontitis

Keywords

Periodontitis, Rheumatoid arthritis, Treatment of periodontitis

Brief summary

Periodontitis is an infectious disease defined by bacteria-mediated inflammation of the supporting tissues of the teeth that if left untreated may ultimately lead to the destruction of the attachment apparatus, culminating in tooth loss. Rheumatoid arthritis is a chronic destructive inflammatory disease characterized by autoantibodies and the accumulation and persistence of an inflammatory infiltrate in the synovial membrane that leads to synovitis and the destruction of the joint architecture. The objective of this study was to evaluate the possible beneficial additional value of non-surgical periodontal therapy on systemic markers of inflammation and clinical and serological parameters of rheumatoid arthritis.

Interventions

PROCEDUREImmediate non-surgical periodontal treatment and oral hygiene instructions

Sponsors

University of Pisa
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects affected by rheumatoid arthritis with a stable therapeutic regimen for at least 3 months preceding the study participation * Subjects with at least 15 teeth * Subjects affected by severe generalized periodontitis that had undergone no periodontal treatment in the 6 months preceding the study participation

Exclusion criteria

* Age younger than 18 years * Pregnancy or breastfeeding * Edentulism * Diagnosis of other autoimmune pathologies, liver disease, diabetes, early/juvenile arthritis or syndromes associated with RA

Design outcomes

Primary

MeasureTime frameDescription
Disease Activity Score 28 (DAS-28)90 daysVariation of DAS-28 90 days after periodontal treatment

Secondary

MeasureTime frameDescription
Erythrocyte Sedimentation Rate (ESR)90 daysVariation of ESR 90 days after periodontal treatment
C-Reactive Protein (CRP)90 daysVariation of CRP 90 days after periodontal treatment
Interleuchin-6 concentration (IL-6)90 daysVariation of IL-6 90 days after periodontal treatment
Oral Health Related Quality of Life (OHRQoL)90 daysVariation of OHRQoL 90 days after periodontal treatment

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026